Note: This vaccine is much better than the previously generated vaccines.
Take home message
1. There are currently more than 230 vaccine candidates under development, with a number of these already receiving EUAs within less than a year since the first report of a SARS-CoV-2 infection.
2. All the leading vaccine candidates are administered via intramuscular injection. However, results emerged from several recent studies highlighting the importance of mucosal immune responses against SARS-CoV-2 infection (Hassan, A. O. et al., CELL, 2020).
3. The vast majority of SARS-CoV-2 vaccines under development require a prime-boost regimen.
4. Massive vaccination campaigns would therefore require billions of doses to satisfy global demand.
5. High vulnerability groups such as health workers and indispensable professionals are the first to receive a vaccine, followed by age groups older than 65 years.
6. Nucleic acid and -sometimes- viral vector platforms that require long-term storage at −70 °C from fabrication to administration can raise severe problems for the distribution of the respective vaccines and limit their use in rural areas (Nikolaos C. Kyriakidis et al., 2021. Nature Vaccines).